Overview

Combination of the Immune Modulator Dimethyl Fumarate With Intraarterial Treatment in Acute Ischemic Stroke

Status:
Not yet recruiting

Trial end date:
2021-12-31

Target enrollment:

Participant gender:

Summary

The investigators conduct this study to investigate whether oral administration of Dimethyl Fumarate, a Food and Drug Administration-approved drug for multiple sclerosis, is safe and effective in combination with intraarterial treatment in patients with Acute Ischemic Stroke.

Phase:

Phase 2

Details

Lead Sponsor:

Xuanwu Hospital, Beijing

Treatments:

Dimethyl Fumarate